Skip to content

CancerIndexthe global index of cancer

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Pulse Data updates Year in cancer Taxonomy Countries Compare Trial intelligence Trial map Drug pipeline Sources Methodology About Trust & policies Data downloads Developers (API)

Loading cancer entity…

CancerIndex

CancerIndex is a research and information platform. It is not a physician, does not diagnose, and does not recommend treatment. Population statistics do not predict individual outcomes.

Every number links to its source and retrieval date. Derived metrics carry a formula version. AI-generated synthesis is not enabled in this phase; all content is database-grounded.

About Trust & policies Data explorer Data downloads Pulse Data update log Developers (API)Sources Methodology Taxonomy Countries Compare Contact · contact@spboucher.ai Status

© 2026 CancerIndex · built and maintained by Simon-Pierre Boucher · contact contact@spboucher.ai · hosted on MacLustr (www.maclustr.io). Source data remains under the license of each provider — see /sources.

Myeloid Neoplasm — Research · CancerIndex

Cancers
Neoplasm
Neoplasm by Morphology
Hematopoietic and Lymphoid Cell Neoplasm
Myeloid Neoplasm

Cancer Family

Myeloid Neoplasm

CI-CAN-00000279Explore in graph →

HematologicNon-malignant1,102 active trials29 approved drugs653 evidence items

NCIt: C9290
OncoTree: MNM
DOID: 0070004

Overview
Statistics
Survival
Genomics22
Variants & evidence653
Drugs61
Trials4789
Research
Rankings
Sources & provenance

Research activity

PubMed record counts

Each count is the number of PubMed records returned by the exact query shown, at the time it was run. Counts are research-activity signals, not quality measures.

Data not yet available

No PubMed query has been run for this entity. Counts require a MeSH-anchored query built from the entity's terminology mappings; the query string is stored with each count so it can be reproduced.

What CancerIndex knows

Trials tab
Methodology: publication counts

Literature

Linked publications (234)

Publications linked to this entity or its descendants, newest first, 25 per page. Link method and validation status are shown; 'candidate' links have not been reviewed.

pubmedProvenance

Source: PubMed (NLM)
Dataset: PubMed E-utilities
Retrieved: Sep 8, 2026
Layer: normalized (units and labels harmonized; values unchanged)

PublishedShowing 1–25 of 234 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.

The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes.
· Blood · 2009 · PMID 19357394 · validated civic_curation pubmed
Novel targeted therapies for Bcr-Abl positive acute leukemias: beyond STI571.
· Oncogene · 2002 · PMID 12476305 · validated civic_curation pubmed
BCR-ABL tyrosine kinase inhibitors in the treatment of Philadelphia chromosome positive chronic myeloid leukemia: a review.
· Leuk Res · 2010 · PMID 20537386 · validated civic_curation pubmed
The PML/RAR alpha fusion gene in the diagnosis and monitoring of acute promyelocytic leukemia.
· Haematologica · 1995 · PMID 7628753 · validated civic_curation pubmed
All trans retinoic acid in acute promyelocytic leukemia.
· Oncogene · 2001 · PMID 11704842 · validated civic_curation pubmed
The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia.
· Blood · 2016 · PMID 27069254 · validated civic_curation pubmed
Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3-Mutated AML.
· N Engl J Med · 2019 · PMID 31665578 · validated civic_curation pubmed
The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties.

Showing 1–25 of 234 publications

← Previous
1
2
…
10
Next →

· Blood · 1998 · PMID 9746770 · validated civic_curation pubmed

Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis.

· Blood · 2014 · PMID 25037629 · validated civic_curation pubmed

Durable responses to imatinib in patients with PDGFRB fusion gene-positive and BCR-ABL-negative chronic myeloproliferative disorders.

· Blood · 2007 · PMID 16960151 · validated civic_curation pubmed

Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia.

· Blood · 2017 · PMID 28588020 · validated civic_curation pubmed

Prognostic significance of FLT3 internal tandem duplication, nucleophosmin 1, and CEBPA gene mutations for acute myeloid leukemia patients with normal karyotype and younger than 60 years: a systematic review and meta-analysis.

· Ann Hematol · 2014 · PMID 24801015 · validated civic_curation pubmed

A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome.

· N Engl J Med · 2003 · PMID 12660384 · validated civic_curation pubmed

Midostaurin approved for FLT3-mutated AML.

· Blood · 2017 · PMID 28546144 · validated civic_curation pubmed

Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML.

· N Engl J Med · 2018 · PMID 29860938 · validated civic_curation pubmed

DNMT3A mutations in acute myeloid leukemia.

· N Engl J Med · 2010 · PMID 21067377 · validated civic_curation pubmed

DNMT3A R882 mutations in patients with cytogenetically normal acute myeloid leukemia and myelodysplastic syndrome.

· Blood Cells Mol Dis · 2014 · PMID 24512939 · validated civic_curation pubmed

Nucleophosmin gene mutations are predictors of favorable prognosis in acute myelogenous leukemia with a normal karyotype.

· Blood · 2005 · PMID 16076867 · validated civic_curation pubmed

Accelerated degradation of PML-retinoic acid receptor alpha (PML-RARA) oncoprotein by all-trans-retinoic acid in acute promyelocytic leukemia: possible role of the proteasome pathway.

· Cancer Res · 1996 · PMID 8674046 · validated civic_curation pubmed

Characteristics and outcome of chronic myeloid leukemia patients with F317L BCR-ABL kinase domain mutation after therapy with tyrosine kinase inhibitors.

· Blood · 2008 · PMID 18818391 · validated civic_curation pubmed

Resistant mutations in CML and Ph(+)ALL - role of ponatinib.

· Biologics · 2014 · PMID 25349473 · validated civic_curation pubmed

Genomic Classification and Prognosis in Acute Myeloid Leukemia.

· N Engl J Med · 2016 · PMID 27276561 · validated civic_curation pubmed

Prognostic factors and outcome of core binding factor acute myeloid leukemia patients with t(8;21) differ from those of patients with inv(16): a Cancer and Leukemia Group B study.

· J Clin Oncol · 2005 · PMID 16110030 · validated civic_curation pubmed

Individual patient data-based meta-analysis of patients aged 16 to 60 years with core binding factor acute myeloid leukemia: a survey of the German Acute Myeloid Leukemia Intergroup.

· J Clin Oncol · 2004 · PMID 15289486 · validated civic_curation pubmed

The JAK2V617F activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukemia, but not in acute lymphoblastic leukemia or chronic lymphocytic leukemia.

· Blood · 2005 · PMID 16081687 · validated civic_curation pubmed